Recombinant Human 4-1BB/TNFRSF9 His Avi-tag Protein, CF

When Recombinant Human 4-1BB Ligand/TNFSF9 (2295-4L) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human 4-1BB/TNFRSF9/CD137 His-tag Avi-tag (Catalog # AVI9220) binds with an ED50 of 20.0-200 ng/mL.

2 μg/lane of Biotinylated Recombinant Human 4-1BB/TNFRSF9 His Avi-tag Protein (Catalog # AVI9220) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 34-41 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human 4-1BB/TNFRSF9 His Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human 4-1BB Ligand/TNFSF9 (Catalog # 2295-4L) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human 4-1BB/TNFRSF9/CD137 His-tag Avi-tag (Catalog # AVI9220) binds with an ED₅₀ of 20.0-200 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human 4-1BB/TNFRSF9/CD137 protein
  

  Human 4-1BB (Leu 24-His 183) Accession # Q07011.1	6-His tag	Avi-tag
  N-terminus		C-terminus

• Accession #: Q07011.1
• N-terminal Sequence: Leu24
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 21 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 34 - 41 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human 4-1BB/TNFRSF9 His Avi-tag Protein, CF

• 4-1BB ligand receptor
• 41BB
• 4-1BB
• CD137 antigen
• CD137
• CD137MGC2172
• CDw137
• FLJ43501
• ILA
• ILAhomolog of mouse 4-1BB
• induced by lymphocyte activation (ILA)
• interleukin-activated receptor, homolog of mouse Ly63
• receptor protein 4-1BB
• T cell antigen ILA
• T-cell antigen 4-1BB homolog
• T-cell antigen ILA
• TNFRSF9
• tumor necrosis factor receptor superfamily member 9
• tumor necrosis factor receptor superfamily, member 9

Background

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine‑rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4+, CD8+, memory CD8+, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells (9, 10). 4-1BB activation enhances CD8+ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17). Our Avi-tag Biotinylated human 4-1BB features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Wang, C. et al. (2009) Immunol. Rev. 229:192.
2. Schwarz, H. et al. (1993) Gene 134:295.
3. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
4. Wen, T. et al. (2002) J. Immunol. 168:4897.
5. Pulle, G. et al. (2006) J. Immunol. 176:2739.
6. Zheng, G. et al. (2004) J. Immunol. 173:2428.
7. Kim, D. et al. (2008) J. Immunol. 180:2062.
8. Lee, S. et al. (2008) Nat. Immunol. 9:917.
9. Choi, B.K. et al. (2009) J. Immunol. 182:4107.
10. Nishimoto, H. et al. (2005) Blood 106:4241.
11. Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
12. Lee, S. et al. (2005) J. Immunol. 174:6803.
13. Ma, B.Y. et al. (2005) Blood 106:2002.
14. Choi, B.K. et al. (2010) J. Immunol. 185:1404.
15. Kim, C. et al. (2011) Diabetes 60:3159.
16. Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
17. Salih, H.R. et al. (2001) J. Immunol. 167:4059.

Bioinformatics

• Uniprot:
  • Q07011.1()